The Lab Equipment Titan Trading at Half the Multiple Just Delivered Another Beat

Danaher (NYSE: DHR | DHR Price Prediction) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories. Danaher is recovering from a major Q2 earnings miss, while Thermo Fisher continues consistent execution.

One Business Stabilizes. The Other Struggles to Recover.

Thermo Fisher posted Q3 revenue of $11.12 billion, up 4.9% year over year, and delivered $5.79 in earnings per share against estimates of $5.50. That marked the company’s 14th earnings beat in the last 16 quarters. The consistency reflects a diversified product portfolio across scientific instruments, reagents, and consumables serving research labs, hospitals, and biopharma customers.

Danaher’s Q3 was more complicated. Revenue reached $6.05 billion, up 4.4%, and the company beat estimates with $1.89 per share versus $1.72 consensus. But that followed a catastrophic Q2, when Danaher reported just $0.77 per share against expectations of $1.18. The 34.7% miss was the largest in years and revealed deeper issues than a single bad quarter. Annual earnings collapsed from $10.95 in 2022 to $4.54 in 2025, a 58.5% decline over three years. Revenue has fallen 18.9% from its 2021 peak of $29.5 billion.

The Valuation Gap Reflects Confidence in Execution

Thermo Fisher trades at 35 times earnings with a forward multiple of 25, while Danaher commands a 48 price-to-earnings ratio despite slower growth. That premium looks hard to justify when Danaher’s quarterly revenue growth of 4.4% barely exceeds Thermo Fisher’s 4.9%, yet Danaher trades at a 37% higher multiple. Thermo Fisher also generates superior profitability with 13.1% return on equity versus Danaher’s 6.84%.

Insider activity reinforces this gap. Danaher’s chairman sold over 500,000 shares in November 2025 at prices around $217 to $220, a concentrated disposal raising questions about leadership confidence. Thermo Fisher saw routine option exercises across multiple executives, but nothing approaching the scale or concentration of Danaher’s selling.

Stock Performance Shows Investor Preference

Over the past year, Thermo Fisher gained 13.1% while Danaher declined 0.2%. The gap widened recently, with Thermo Fisher up 9.3% over the last month versus Danaher’s 6.4%. Both stocks rallied in early January 2026, but Thermo Fisher continues to pull ahead.

Key Differences Between the Two Companies

Thermo Fisher has demonstrated consistent execution, beating estimates 14 of the last 16 quarters. The company generates a 13% return on equity versus Danaher’s 6.84% and trades at a lower valuation multiple of 35x earnings versus 48x. Danaher’s earnings have fallen 58% over three years, though the company maintains a slightly higher operating margin of 20.7% compared to Thermo Fisher’s 19.3%. The valuation premium Danaher commands appears difficult to justify given the divergent earnings trajectories and profitability metrics.